Year archive

Oncoinvent ASA — 2025 filings

All 110 regulatory filings released by Oncoinvent ASA (OCIN) in 2025, sourced directly from the official regulator.

110 Filings

2025 Period

2025 filings (110)

Filing	Released	Lang
Oncoinvent ASA: Grant of share options - mandatory notification of trade - Attachment: 20251222_Notifications_of_transactions_Receipt_of_share_options_old_options.pdf Director's Dealing	2025-12-22	English
Oncoinvent ASA: Grant of share options - mandatory notification of trade - Attachment: 20251222_Notifications_of_transactions_Receipt_of_share_options_new_grant.pdf Director's Dealing	2025-12-22	English
Oncoinvent ASA: Grant of share options - mandatory notification of trade Director's Dealing	2025-12-22	English
Oncoinvent ASA: Notice of Extraordinary General Meeting - Attachment: Oncoinvent_ASA_Notice_EGM_8_January_2026.pdf Proxy Solicitation & Information Statement	2025-12-18	Norwegian
Oncoinvent ASA: Notice of Extraordinary General Meeting AGM Information	2025-12-18	English
Oncoinvent ASA: New share capital registered Share Issue/Capital Change	2025-12-10	English
Flaggemelding – Hadean Ventures AS / HVentures AB / Hadean Growth Fund I AS1 – Oncoinvent AS (ONCIN) Major Shareholding Notification	2025-12-08	Norwegian
Oncoinvent Announces Publication of Phase 1 Study Results for Radspherin® in Ovarian Cancer in Gynecologic Oncology Regulatory Filings	2025-12-08	English
Oncoinvent ASA: Notification of trade - primary insider/close associate - Attachment: 2025_12_05_PDMR_Attachment_subscription_and_allocation_of_UWC_shares.pdf Director's Dealing	2025-12-08	English
Oncoinvent ASA: Notification of trade - primary insider/close associate Director's Dealing	2025-12-08	English
NOTIFICATION OF MAJOR HOLDINGS - Attachment: Notification of major holding Linc AB 2025-12-05 sent to Oslo Boers.pdf Major Shareholding Notification	2025-12-05	English
NOTIFICATION OF MAJOR HOLDINGS Major Shareholding Notification	2025-12-05	English
Oncoinvent ASA: Resolution to increase the share capital in connection with settlement of underwriting fee Share Issue/Capital Change	2025-12-05	English
Oncoinvent ASA: Minutes from Extraordinary General Meeting - Attachment: 2025_12_05_EGM_minutes_sign.pdf AGM Information	2025-12-05	Norwegian
Oncoinvent ASA: Minutes from Extraordinary General Meeting AGM Information	2025-12-05	English
Flaggemelding - MP Pensjon PK Major Shareholding Notification	2025-12-03	Norwegian
Oncoinvent ASA: Notification of trade - primary insider/close associate - Attachment: 2025_12_02_PDMR_Attachment_allocation_of_new_shares.pdf Director's Dealing	2025-12-02	English
Oncoinvent ASA: Notification of trade - primary insider/close associate - Attachment: 2025_12_02_Allocation_to_PDMRs_CAs.pdf Director's Dealing	2025-12-02	English
Oncoinvent ASA: Notification of trade - primary insider/close associate Director's Dealing	2025-12-02	English
Oncoinvent ASA: Final results of the rights issue Share Issue/Capital Change	2025-12-02	English
Oncoinvent ASA: Preliminary results of the rights issue Capital/Financing Update	2025-12-01	English
Oncoinvent ASA: Last day of the subscription period in the rights issue Capital/Financing Update	2025-12-01	English
Oncoinvent ASA: Notification of trade - primary insider/close associate - Attachment: 2025_11_27_PDMR_Attachment_exercise_of_subscription_rights.pdf Director's Dealing	2025-11-27	English
Oncoinvent ASA: Notification of trade - primary insider/close associate - Attachment: 2025_11_27_Notification_of_trade_primary_insiders.pdf Share Issue/Capital Change	2025-11-27	English
Oncoinvent ASA: Notification of trade - primary insider/close associate Director's Dealing	2025-11-27	English
Oncoinvent ASA: Last day of trading in subscription rights Capital/Financing Update	2025-11-25	English
Oncoinvent ASA: Commencement of the subscription period for the Rights Issue Capital/Financing Update	2025-11-17	English
Oncoinvent ASA: Notice of Extraordinary General Meeting in connection with the Rights Issue - Attachment: Oncoinvent_ASA_Notice_of_EGM_2025_12_05.pdf Proxy Solicitation & Information Statement	2025-11-14	Norwegian
Oncoinvent ASA: Notice of Extraordinary General Meeting in connection with the Rights Issue AGM Information	2025-11-14	English
Oncoinvent ASA - Receipt of subscription rights in the rights issue by primary insiders and their close associates - Attachment: 2025_11_14_PDMR_Attachment2.pdf Director's Dealing	2025-11-14	English
Oncoinvent ASA - Receipt of subscription rights in the rights issue by primary insiders and their close associates Share Issue/Capital Change	2025-11-14	English
Oncoinvent ASA - Receipt of subscription rights in the rights issue by primary insiders and their close associates - Attachment: 2025_11_14_PDMR_Attachment.pdf Director's Dealing	2025-11-14	English
Oncoinvent ASA - Receipt of subscription rights in the rights issue by primary insiders and their close associates - Attachment: 2025_11_14_Receipt_of_subscription_rights_in_the_rights_issue_by_primar Share Issue/Capital Change	2025-11-14	English
Oncoinvent ASA - Receipt of subscription rights in the rights issue by primary insiders and their close associates Share Issue/Capital Change	2025-11-14	English
Oncoinvent ASA: EX. SUBSCRIPTION RIGHTS IN RIGHTS ISSUE TODAY Share Issue/Capital Change	2025-11-12	English
Oncoinvent ASA: Terms of the underwritten Rights Issue Capital/Financing Update	2025-11-11	English
Oncoinvent ASA: Updated Key Information related to the contemplated Rights Issue Share Issue/Capital Change	2025-11-11	English
Reminder: Invitation to presentation of Q3 2025 company update on November 4[th], 2025 Report Publication Announcement	2025-11-03	English
NOTIFICATION OF MAJOR HOLDINGS - Attachment: Notification of major holding Linc AB 2025-11-03 sent to Oslo Boers.pdf Major Shareholding Notification	2025-11-03	English
NOTIFICATION OF MAJOR HOLDINGS Major Shareholding Notification	2025-11-03	English
Disclosure of large shareholding Major Shareholding Notification	2025-11-03	English
Flaggemelding Major Shareholding Notification	2025-11-03	Norwegian
Flaggemelding – Hadean Ventures AS / HVentures AB – Oncoinvent AS (ONCIN) Major Shareholding Notification	2025-11-03	Norwegian
Mandatory notification of trade - Attachment: PDMR_Attachment_allocation_of_consideration_shares.pdf Director's Dealing	2025-11-03	English
Mandatory notification of trade - Attachment: 2025_11_03_vederlags_aksjer.pdf Director's Dealing	2025-11-03	English
Mandatory notification of trade Director's Dealing	2025-11-03	English
Oncoinvent appoints Dr. Ramzi Amri as new CFO - Attachment: 251031_Oncoinvent_CFO_PR.pdf Board/Management Information	2025-10-31	English
Oncoinvent appoints Dr. Ramzi Amri as new CFO Board/Management Information	2025-10-31	English
Financial calendar Report Publication Announcement	2025-10-29	English
Merger of BerGenBio and Oncoinvent completed - Attachment: 2025_10_29_merger_completed.pdf M&A Activity	2025-10-29	English
Merger of BerGenBio and Oncoinvent completed M&A Activity	2025-10-29	English
Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin® to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies - Regulatory Filings	2025-10-29	English
Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin® to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies Regulatory Filings	2025-10-29	English
BerGenBio and Oncoinvent - Last day of trading in the shares of Oncoinvent - Attachment: 2025_10_28_last_day_of_trading.pdf Delisting Announcement	2025-10-29	English
BerGenBio and Oncoinvent - Last day of trading in the shares of Oncoinvent Delisting Announcement	2025-10-29	English
BerGenBio and Oncoinvent - Key Dates for Completion of Merger - Attachment: 2025_10_24_BerGenBio_and_Oncoinvent_Joint_Stock_Exchange_Announcement_re_Key_Dates_for_Completion_of_Merger.pdf M&A Activity	2025-10-24	English
BerGenBio and Oncoinvent - Key Dates for Completion of Merger M&A Activity	2025-10-24	English
Financial calendar Report Publication Announcement	2025-10-20	English
Finansiell kalender Report Publication Announcement	2025-10-20	Norwegian
Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer - Attachment: 2025_10_08_Oncoinvent_PM_OC_Ph1_24m.pdf Regulatory Filings	2025-10-08	English
Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer Regulatory Filings	2025-10-08	English
Oncoinvent ASA: Updated information regarding the contemplated Rights Issue and Merger - Attachment: 2025_09_17_Announcement_updated_timeline.pdf Share Issue/Capital Change	2025-09-17	English
Oncoinvent ASA: Updated information regarding the contemplated Rights Issue and Merger Share Issue/Capital Change	2025-09-17	English
Oncoinvent ASA: Updated Key Information related to the contemplated Rights Issue - Attachment: 2025_09_17_Announcement_key_info_rights_issue.pdf Share Issue/Capital Change	2025-09-17	English
Oncoinvent ASA: Updated Key Information related to the contemplated Rights Issue Share Issue/Capital Change	2025-09-17	English
Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer - Attachment: Oncoinvent_Pressrelease_1H_2025_results.pdf Earnings Release H1 2025	2025-08-27	English
Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer - Attachment: Oncoinvent_1H25_presentation.pdf Investor Presentation	2025-08-27	English
Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer - Attachment: Oncoinvent_1H25_report.pdf Interim / Quarterly Report H1 2025	2025-08-27	English
Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer Earnings Release H1 2025	2025-08-27	English
Oncoinvent ASA invites to a webcast presentation of 1H 2025 on Wednesday 27 August 2025 Report Publication Announcement	2025-08-22	English
Oncoinvent shareholders approve the merger plan with BerGenBio - Attachment: Oncoinvent_Minutes_EGM_2025_08_04.pdf Declaration of Voting Results & Voting Rights Announcements	2025-08-04	Norwegian
Oncoinvent shareholders approve the merger plan with BerGenBio AGM Information	2025-08-04	English
Oncoinvent ASA: Notice of Extraordinary General Meeting - Attachment: Oncoinvent_ASA_Notice_of_EGM_4_August_2025_vF.pdf AGM Information	2025-07-03	Norwegian
Oncoinvent ASA: Notice of Extraordinary General Meeting AGM Information	2025-07-03	English
Announcement of fully underwritten rights issue - Attachment: Attachment_overview_of_underwriters_vf.pdf Share Issue/Capital Change	2025-06-30	English
Announcement of fully underwritten rights issue - Attachment: Joint_Press_Release_RI.pdf Capital/Financing Update	2025-06-30	English
Announcement of fully underwritten rights issue Capital/Financing Update	2025-06-30	English
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue - Attachment: Joint_Press_Release_Merger_Transactio M&A Activity	2025-06-30	English
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue M&A Activity	2025-06-30	English
Oncoinvent (ONCIN): Invitation to Presentation of Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases - Attachment: 2025-06-18 Presentation of Ph Regulatory Filings	2025-06-18	English
Oncoinvent (ONCIN): Invitation to Presentation of Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases Regulatory Filings	2025-06-18	English
Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases - Attachment: 2506 Oncoinvent PM CRC Ph1-2a.pdf Earnings Release Q2 2025	2025-06-18	English
Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases Earnings Release Q1 2025	2025-06-18	English
Minutes from the annual general meeting 2025 AGM Information	2025-05-14	Norwegian
Minutes from the annual general meeting 2025 AGM Information	2025-05-14	English
Notice of Annual General Meeting AGM Information	2025-04-30	Norwegian
Notice of Annual General Meeting AGM Information	2025-04-30	English
Oncoinvent ASA: Annual Report 2024 Annual Report FY 2024	2025-04-28	English
Oncoinvent ASA: Annual Report 2024 Report Publication Announcement FY 2024	2025-04-28	English
Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update Report Publication Announcement	2025-04-28	English
Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update Report Publication Announcement	2025-04-28	English
Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression Earnings Release Q1 2025	2025-04-28	English
Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression Earnings Release Q1 2025	2025-04-28	English
Financial calendar Report Publication Announcement	2025-04-28	English
Oncoinvent ASA Announces Positive Safety Review of Lead-In Cohort, Advances to Randomised Part of Ongoing Phase 2 Trial of Radspherin® in Ovarian Cancer Patients Regulatory Filings	2025-03-25	English
Oncoinvent ASA: Mandatory notification of trade Director's Dealing	2025-03-05	English
Oncoinvent ASA: Fourth Quarter 2024 Update and Results Interim / Quarterly Report Q4 2024	2025-02-27	English
Oncoinvent ASA: Fourth Quarter 2024 Update and Results Earnings Release Q4 2024	2025-02-27	English
Oncoinvent ASA reports completed inclusion in the initial safety lead-in cohort of the phase 2 trial of Radspherin® in Ovarian Cancer Patients Regulatory Filings	2025-02-27	English
Oncoinvent ASA: Invitation to Result Presentation Q4 2024 Report Publication Announcement	2025-02-20	English
Oncoinvent ASA to present at various conferences Regulatory Filings	2025-02-19	English
Oncoinvent ASA: Registration of new share capital Share Issue/Capital Change	2025-02-18	English
Oncoinvent ASA: Final results of the subsequent offering and allocation of offer shares Share Issue/Capital Change	2025-02-06	English
Oncoinvent ASA: Last day of the subscription period in the subsequent offering Capital/Financing Update	2025-02-06	English
Oncoinvent ASA: Grant of share options - mandatory notification of trade Remuneration Information	2025-02-04	English
Oncoinvent ASA: Grant of share options - mandatory notification of trade Director's Dealing	2025-02-04	English
Oncoinvent ASA: Commencement of subscription period for subsequent offering Capital/Financing Update	2025-01-23	English
Oncoinvent ASA: Key information relating to subsequent offering Share Issue/Capital Change	2025-01-22	English
Oncoinvent ASA: Resolution to increase the share capital in connection with subsequent offering Capital/Financing Update	2025-01-22	English
Oncoinvent ASA: Resolution to increase the share capital in connection with subsequent offering Capital/Financing Update	2025-01-22	English